APACI and Dreamgenics have signed a framework agreement of institutional collaboration to promote the genetic diagnosis of congenital cardiovascular diseases, as well as to develop research projects and training activities related to them.
The Association of Parents and Friends of Congenital Cardiopathies (APACI) is an association of public utility, national and independent that watches over and defends the fundamental right to health of those affected by congenital cardiopathies. For its part, Dreamgenics is a biotechnology company that is a reference in Spain in the analysis of genomic data and genetic diagnosis.
During the signing of the framework agreement, Carlos Martínez, CEO of Dreamgenics, stressed that the aim of this agreement is to provide APACI with a new tool to make available to all its members in order to help in the diagnosis of congenital heart disease. "This agreement is a demonstration of Dreamgenics' firm commitment to working on the development of Personalised Precision Medicine and we are delighted to be able to collaborate with APACI to bring it to all its members".
Along the same lines, Juana Mª Jara, President of APACI, said "An accurate genetic diagnosis associated with congenital heart disease will allow us to identify whether there may be other organs involved in addition to the heart, as well as to make a possible clinical prognosis, to make a family risk calculation allowing us to determine future reproductive risks and to identify other family members at risk of suffering the disease. Technological advances and knowledge in genetics are essential, so this agreement is a great opportunity for APACI and its families.
APACI and Dreamgenics have already started working on the first initiatives resulting from this agreement and are confident that they will be of great use to their partners.